Methods of treating apol-1 dependent focal segmental glomerulosclerosis
US-2021275496-A1 · Sep 9, 2021 · US
Inhibitors of APOL1 and methods of using same
US11618746B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11618746-B2 |
| Application number | US-201916717099-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 17, 2019 |
| Priority date | Dec 17, 2018 |
| Publication date | Apr 4, 2023 |
| Grant date | Apr 4, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound chosen from compounds of Formula (I) deuterated derivatives thereof, pharmaceutically acceptable salts of those compounds and deuterated derivatives, and solvates of any of the foregoing, wherein: (i) each R 1 is independently chosen from halogen groups, hydroxy, thiol, amino, cyano, —OC(O)C 1 -C 6 linear, —OC(O)C 3 -C 6 branched, and —OC(O)C 3 -C 6 cyclic alkyl groups, —C(O)OC 1 -C 6 linear, —C(O)OC 3 -C 6 branched, and —C(O)OC 3 -C 6 cyclic alkyl groups, —NHC(O)C 1 -C 6 linear, —NHC(O)C 3 -C 6 branched, and —NHC(O)C 3 -C 6 cyclic alkyl groups, —C(O)NHC 1 -C 6 linear, —C(O)NHC 3 -C 6 branched, and —C(O)NHC 3 -C 6 cyclic alkyl groups, —NHC(O)C 5 -C 6 aryl groups, —C(O)NHC 5 -C 6 aryl groups, —NHC(O) 5- to 6-membered heteroaryl groups, —C(O)NH 5- to 6-membered heteroaryl groups, —NHS(O) 2 C 1 -C 6 linear, —NHS(O) 2 C 3 -C 6 branched, and —NHS(O) 2 C 3 -C 6 cyclic alkyl groups, —S(O) 2 NHC 1 -C 6 linear, —S(O) 2 NHC 3 -C 6 branched, and —S(O) 2 NHC 3 -C 6 cyclic alkyl groups, —NHS(O) 2 C 5 -C 6 aryl groups, —S(O) 2 NHC 5 -C 6 aryl groups, —NHS(O) 2 5- to 6-membered heteroaryl groups, —S(O) 2 NH 5- to 6-membered heteroaryl groups, —NHC(O)NHC 1 -C 6 linear, —NHC(O)NHC 3 -C 6 branched, and —NHC(O)NHC 3 -C 6 cyclic alkyl groups, —NHC(O)NHC 5 -C 6 aryl groups, —NHC(O)NH 5- to 6-membered heteroaryl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkyl groups, C 2 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkenyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic hydroxyalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkoxy groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic thioalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloaminoalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic halothioalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloalkoxy groups, benzyloxy, benzylamino, or benzylthio groups, 3 to 6-membered heterocycloalkenyl groups, 3 to 6-membered heterocycloalkyl groups, and 5 and 6-membered heteroaryl groups; (ii) each R 2 is independently chosen from halogen groups, hydroxy, thiol, amino, cyano, —NHC(O)C 1 -C 6 linear, —NHC(O)C 3 -C 6 branched, and —NHC(O)C 3 -C 6 cyclic alkyl groups, —C(O)NHC 1 -C 6 linear, —C(O)NHC 3 -C 6 branched, and —C(O)NHC 3 -C 6 cyclic alkyl groups, —NHC(O)C 5 -C 6 aryl groups, —C(O)NHC 5 -C 6 aryl groups, —NHC(O) 5- to 6-membered heteroaryl groups, —C(O)NH 5- to 6-membered heteroaryl groups, —NHS(O) 2 C 1 -C 6 linear, —NHS(O) 2 C 3 -C 6 branched, and —NHS(O) 2 C 3 -C 6 cyclic alkyl groups, —S(O) 2 NHC 1 -C 6 linear, —S(O) 2 NHC 3 -C 6 branched, and —S(O) 2 NHC 3 -C 6 cyclic alkyl groups, —NHS(O) 2 C 5 -C 6 aryl groups, —S(O) 2 NHC 5 -C 6 aryl groups, —NHS(O) 2 5- to 6-membered heteroaryl groups, —S(O) 2 NH 5- to 6-membered heteroaryl groups, —NHC(O)NHC 1 -C 4 linear, —NHC(O)NHC 3 -C 4 branched, and —NHC(O)NHC 3 -C 4 cyclic alkyl groups, —NHC(O)NHC 5 -C 6 aryl groups, —NHC(O)NH 5- to 6-membered heteroaryl groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic alkyl groups, C 2 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic alkenyl groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic hydroxyalkyl groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic alkoxy groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic thioalkyl groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic haloalkyl groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic haloaminoalkyl groups, C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic halothioalkyl groups, and C 1 -C 4 linear, C 3 -C 4 branched, and C 3 -C 4 cyclic haloalkoxy groups; (iii) m is chosen from 0, 1, 2, 3, and 4; (iv) n is chosen from 0, 1, 2, 3, 4, and 5; (v) Y is chosen from divalent C 1 -C 8 linear and C 3 -C 8 branched alkyl groups, divalent C 1 -C 8 linear and branched alkoxy groups, divalent C 1 -C 8 linear and C 3 -C 8 branched aminoalkyl groups, and divalent C 1 -C 8 linear and C 3 -C 8 branched thioalkyl groups, wherein the divalent alkyl groups, divalent alkoxy groups, divalent aminoalkyl groups, and divalent thioalkyl groups are optionally substituted with at least one group chosen from C 1 -C 6 alkyl groups, C 5 -C 6 aryl groups, 5 to 6-membered heteroaryl groups, halogen groups, hydroxy, and amino; (vi) each of R 3 and R 1 is independently chosen from hydrogen, hydroxy, thiol, amino, halogen groups, C 1 -C 3 linear, C 3 branched, and C 3 cyclic alkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic hydroxyalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkoxy groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic thioalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloaminoalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic halothioalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloalkoxy groups, or R 3 and R 4 , together with the carbon atom to which they are attached, form a C 3 -C 6 cycloalkyl group or carbonyl group; (vii) each of R 5 and R 6 is independently chosen from hydrogen, thiol, amino, halogen groups, hydroxy, C 1 -C 3 linear, C 3 branched, and C 3 cyclic alkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic hydroxyalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and cyclic alkoxy groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic thioalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloaminoalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic halothioalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic haloalkoxy groups, —OC(O)C 1 -C 6 linear, —OC(O)C 3 -C 6 branched, and —OC(O)C 3 -C 6 cyclic alkyl groups, —C(O)OC 1 -C 6 linear, —C(O)OC 3 -C 6 branched, and —C(O)OC 3 -C 6 cyclic alkyl groups, —NHC(O)C 1 -C 6 linear, —NHC(O)C 3 -C 6 branched, and —NHC(O)C 3 -C 6 cyclic alkyl groups, —C(O)NHC 1 -C 6 linear, —C(O)NHC 3 -C 6 branched, and —C(O)NHC 3 -C 6 cyclic alkyl groups, —NHC(O)C 5 -C 6 aryl groups, —C(O)NHC 5 -C 6 aryl groups, —NHC(O) 5- to 6-membered heteroaryl groups, —C(O)NH 5- to 6-membered heteroaryl groups, —NHS(O) 2 C 1 -C 6 linear, —NHS(O) 2 C 3 -C 6 branched, and —NHS(O) 2 C 3 -C 6 cyclic alkyl groups, —S(O) 2 NHC 1 -C 6 linear, —S(O) 2 NHC 3 -C 6 branched, and —S(O) 2 NHC 3 -C 6 cyclic alkyl groups, —NHS(O) 2 C 5 -C 6 aryl groups, —S(O) 2 NHC 5 -C 6 aryl groups, —NHS(O) 2 5- to 6-membered heteroaryl groups, —S(O) 2 NH 5- to 6-membered heteroaryl groups, —NHC(O)NHC 1 -C 6 linear, —NHC(O)NHC 3 -C 6 branched, and —NHC(O)NHC 3 -C 6 cyclic alkyl groups, —NHC(O)NHC 5 -C 6 aryl groups, and —NHC(O)NH 5- to 6-membered heteroaryl groups; and (viii) each of R 7 , R 8 , and R 9 is independently chosen from hydrogen, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic hydroxyalkyl groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3 -C 6 cyclic alkoxy groups, C 1 -C 6 linear, C 3 -C 6 branched, and C 3
Assignees
Inventors
Classifications
not condensed and containing further heterocyclic rings, e.g. cromakalim · CPC title
Crystalline forms, e.g. polymorphs · CPC title
of the kidneys · CPC title
- C07D403/12Primary
linked by a chain containing hetero atoms as chain links · CPC title
Isotopically modified compounds, e.g. labelled · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11618746B2 cover?
- The disclosure provides a compound of Formula (I), including deuterated derivatives, pharmaceutically acceptable salts, and solvates thereof, solid state forms of those compounds, compositions comprising those compounds and solid forms, and methods of using the same, including use in treating focal segmental glomerulosclerosis (FSGS) and/or non-diabetic kidney disease (NDKD).
- Who is the assignee on this patent?
- Vertex Pharma
- What technology area does this patent fall under?
- Primary CPC classification C07D403/12. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).